Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Hepatoma cells 24 h after plating were treated with vehicle (DMSO), regorafenib (REGO, 0.5 µM), PDE5 inhibitor (sildenafil, 2 µM); or the drugs in combination. 24 hours after treatment cells were isolated and viability determined by trypan blue (n=3, SEM). *P 0.05

    J Cell Physiol, 2015, 230(9): 2281-98. Regorafenib (BAY 73-4506) purchased from Selleck.

    Cytotoxic effects of regorafenib in vitro on PDAC cell lines. Analysis of cell viability (high cell viability corresponds to high OD measured photometrically) after 72-h incubation with 2 μM regorafenib or with a vehicle control (0.2% DMSO) (co). The data of five independent experiments are presented with SE and analyzed with the unpaired two-tailed t test, *p < 0.05, **p < 0.01, and ***p < 0.001.

    Naunyn Schmiedebergs Arch Pharmacol, 2017, 390(11):1125-1134. Regorafenib (BAY 73-4506) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B M2q4eWFxd3C2b4Ppd{BCe3OjeR?= MoHiNgKBmzYEoN88US=> MU[0PEBp NI[2RpZqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MmCyNlY{Ojl4MEi=
PLC/PRF/5  MX7BdI9xfG:|aYOgRZN{[Xl? NIPwbHky6oDVNdMg{txO Mme1OFghcA>? MVzpcohq[mm2czDj[YxtKGe{b4f0bC=> MUOyOlMzQTZyOB?=
HepG2  MVvBdI9xfG:|aYOgRZN{[Xl? M1rCbVHjiJN3wrFOwG0> MWi0PEBp NY\lc5NOcW6qaXLpeJMh[2WubDDndo94fGh? M3;ST|I3OzJ7NkC4
HEK293 M4HC[mZ2dmO2aX;uJGF{e2G7 Mli3NE426oDLzszN NH;rNYwzNzRxNjDo Ml\KdoVlfWOnczDHVnA4QCCneIDy[ZN{cW:w M4r2OVI2QDV6MEOy
GEO Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fzbVAvODFvMkCg{txO MnWxPVYhcA>? NF;6WmdFVVOR MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFr5[4kzPTh|OEO5NS=>
SW48 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XD[VAvODFvMkCg{txO NXHxZ|lKQTZiaB?= NHrWdm1FVVOR MV7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn3SNlU5Ozh|OUG=
HT29 NWLXUYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvsPGgxNjBzLUKwJO69VQ>? MWq5OkBp MlnSSG1UVw>? M2HWWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVfxXopNOjV6M{izPVE>
SW480 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HlZVAvODFvMkCg{txO MYK5OkBp M{nWSGROW09? M3my[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHvmbWgzPTh|OEO5NS=>
SW620 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuwMlAyNTJyIN88US=> M1;KUVk3KGh? M3m4eGROW09? M4fEdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYPROlBLOjV6M{izPVE>
HCT116 NUPhZZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfOSo0xNjBzLUKwJO69VQ>? M1HHb|k3KGh? MVvEUXNQ MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYjSN4d7OjV6M{izPVE>
LOVO NYry[WdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe5cmoxNjBzLUKwJO69VQ>? NV7rdIZIQTZiaB?= MXnEUXNQ MonDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV6yOVg{QDN7MR?=
HCT150 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rke|AvODFvMkCg{txO NFW1PWk6PiCq M4fybGROW09? MlznbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUPp[WhbOjV6M{izPVE>
SW48-CR M{nIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXSNE4xOS1{MDFOwG0> NX;TeHpWQTZiaB?= NITyN2JFVVOR NUHiR4J2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnjUNlU5Ozh|OUG=
GEO-CR M3THZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[wMlAyNTJyIN88US=> NUe0NZk3QTZiaB?= MmnESG1UVw>? MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFXRRnozPTh|OEO5NS=>
KB-31 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfVfZVKSzVyPUWuOeKyOC5|IH7N NW\3dnI2OjV5NUOzOlE>
KB-G2 Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD3TWM2OD17LkJCtVAvOSCwTR?= MmfGNlU4PTN|NkG=
LLC-PK1 NITNZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PuTGlEPTB;NEKuNOKyOy5{IH7N NHG4OJYzPTd3M{O2NS=>
LLC-PK1/MRP2 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTh{LkVCtVIvPyCwTR?= NGfoTpkzPTd3M{O2NS=>
HEK293 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\nNGlEPTB;MUGuNOKyOS5{IH7N NV;WWXdwOjV5NUOzOlE>
HEK293/OATP1B1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIftXodKSzVyPU[uNuKyOC5|IH7N MWeyOVc2OzN4MR?=
HROC18 MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3lb|dEUUN3ME2xMlMh|ryP NGK1e4QzPTNyOUmxOC=>
HROC24 NFXGdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLoSHBkUUN3ME20MlYh|ryP MWGyOVMxQTlzNB?=
HROC43 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7rTWM2OD13LkOg{txO Mom2NlU{ODl7MUS=
HROC46 NWnL[JNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmxOWpKSzVyPUKuOEDPxE1? MX6yOVMxQTlzNB?=
RJ345 NEjwWHBHfW6ldHnvckBCe3OjeR?= MV:wMlUwPSEQvF2= NVy2XnZ{OjRiaB?= M4T2RWROW09? MWDpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= M1rMelI2OjV|OUm0
RJ348 NEfhTVBHfW6ldHnvckBCe3OjeR?= MWqwMlUwPSEQvF2= M333blI1KGh? NEn2RmdFVVOR NXLBOpJncW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MljsNlUzPTN7OUS=
MCF-7 Mn7jSpVv[3Srb36gRZN{[Xl? M3PoZ|AvPS93IN88US=> M4fkb|I1KGh? MUjEUXNQ NWfPW5ZbcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v M{TRelI2OjV|OUm0
MDA-MB-231 MmXRSpVv[3Srb36gRZN{[Xl? NHr4Z2sxNjVxNTFOwG0> MmjVNlQhcA>? MXHEUXNQ MojobY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u NV7Kfo83OjV{NUO5PVQ>
HT15 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPjNU0zOCEQvF2= NV;1RmgyPDhiaB?= M3e5XIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4rTV|I2ODdzMEG4
DLD1 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnlRZV5OS1{MDFOwG0> NGX1OnM1QCCq MkLPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWiyOVA4OTBzOB?=
HT-29 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HLNFEuOjBizszN Mor6OFghcA>? NYK4WHBucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWHrVJBtOjVyN{GwNVg>
Hct-116 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2NU0zOCEQvF2= NUKzdVkxPDhiaB?= MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NV;4dnM{OjVyN{GwNVg>
HT15 NX7WcJAySXCxcITvd4l{KEG|c3H5 NV[zTIZKOS1zMDFOwG0> MUK0PEBp MmfLbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWrQZowyOjVyN{GwNVg>
DLD1 MW\BdI9xfG:|aYOgRZN{[Xl? M17Fe|EuOTBizszN M2TjXlQ5KGh? NF;vcpVqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2P2eFI2ODdzMEG4
HT-29 M13vfWFxd3C2b4Ppd{BCe3OjeR?= NYDYXm9sOS1zMDFOwG0> NHP5S2s1QCCq NXfG[2VzcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHrReowzPTB5MUCxPC=>
Hct-116 MmfwRZBweHSxc3nzJGF{e2G7 MmHmNU0yOCEQvF2= NFf2SVE1QCCq NXr0ZYxYcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXHkfnA{OjVyN{GwNVg>
GBM5 NUixdVFoSXCxcITvd4l{KEG|c3H5 NVr2OYNROC534pETNU4x6oDLzszN M4rnOFI1KGh? NVj5dm1tTE2VTx?= NUnNe5IycW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp Ml74NlQ6OTF{MUW=
GBM6 M{L2TmFxd3C2b4Ppd{BCe3OjeR?= NHfxTIMxNjYkgKOxMlDjiIoQvF2= NGDLNVQzPCCq M{jJVmROW09? MmG3bY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo NWDLVXRkOjR7MUGyNVU>
GBM12 MorFRZBweHSxc3nzJGF{e2G7 MkTPNE426oDVMT6w5qCK|ryP NWm2eWpLOjRiaB?= NGnNb5FFVVOR NWmxeI5ScW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp MYmyOFkyOTJzNR?=
GBM14  NFfjZ5NCeG:ydH;zbZMhSXO|YYm= NILBdVMxNjYkgKOxMlDjiIoQvF2= Mn7TNlQhcA>? NVzRZYZPTE2VTx?= M1nSPYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> MlK3NlQ6OTF{MUW=
Hep3B M16xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW0[HAy6oDVMj61xsDPxE1? NFvUNmEzPC92OD:3NkBp NYrUWFM6cW6qaXLpeJMh[2WubDDndo94fGh? NW\GdYdiOjR6OEW4PVA>
PLC/PRF/5  NVP3eGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfCNgKBmzJwNdMg{txO NWqyPHNqOjRxNEivO|IhcA>? NELLTpFqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NUjqOYlKOjR6OEW4PVA>
HepG2  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XrZ|HjiJN{LkZCpO69VQ>? MXyyOE81QC95MjDo MVvpcohq[mm2czDj[YxtKGe{b4f0bC=> M2r0fFI1QDh3OEmw
HCT116  MXHGeY5kfGmxbjDBd5NigQ>? MVixNE8zOC92MDFOwG0> NUntN4E{OjRiaB?= MmS4bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MYiyOFc3OzZzMR?=
Lim2405 NF3rdHdHfW6ldHnvckBCe3OjeR?= NIrlTI41OCEQvF2= MoXTNlQhcA>? NHXlOppqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MWGyOFc3OzZzMR?=
LoVo M1XUNGZ2dmO2aX;uJGF{e2G7 NW\0dGRZPDBizszN MkjlNlQhcA>? M4\MRYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M{nPPVI1PzZ|NkGx
Lim1215 NHPEdZZHfW6ldHnvckBCe3OjeR?= M13INVQxKM7:TR?= MYCyOEBp MVPpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NUfHbHd6OjR5NkO2NVE>
SW48 MWXGeY5kfGmxbjDBd5NigQ>? MX[0NEDPxE1? NYe0S5l3OjRiaB?= MVfpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M3HEb|I1PzZ|NkGx
RKO  MlrPSpVv[3Srb36gRZN{[Xl? MXO0NEDPxE1? NHnFPJEzPCCq MUfpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MUeyOFc3OzZzMR?=
SW837 MX\GeY5kfGmxbjDBd5NigQ>? NIW4VWk1OCEQvF2= NIfTOFEzPCCq MlTSbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MmLvNlQ4PjN4MUG=
SW1463 MoLwSpVv[3Srb36gRZN{[Xl? NX72VmVlPDBizszN NFXEWGczPCCq NXLHZ2xTcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MV:yOFc3OzZzMR?=
SW480 MUjGeY5kfGmxbjDBd5NigQ>? M1;5WVQxKM7:TR?= M3LBflI1KGh? Mlz5bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NYD3Xo54OjR5NkO2NVE>
Vaco432 M3iyVWZ2dmO2aX;uJGF{e2G7 MnvDOFAh|ryP NI\vS3QzPCCq Mnu4bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ Mmr1NlQ4PjN4MUG=
Vaco400 MnrZSpVv[3Srb36gRZN{[Xl? NVLH[3hyPDBizszN MWKyOEBp MnX6bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ M1u1e|I1PzZ|NkGx
DLD1 NF\HXHhHfW6ldHnvckBCe3OjeR?= NV;VSnBNPDBizszN M3\WXlI1KGh? M1nx[Ylv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M3K1fVI1PzZ|NkGx
HT29  MmHpSpVv[3Srb36gRZN{[Xl? Mk\MOFAh|ryP M3na[VI1KGh? NI\XOYNqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NX3tTVQxOjR5NkO2NVE>
PLC/PRF/5  M3TRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDjNgKBmzYEtV2= NHfEclYzPC92OD:3NkBp MnfpbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MmrFNlMyPjlzNEi=
HepG2 M2rxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi0d5IzOeLCk{ZCuW0> M3XrWFI1NzR6L{eyJIg> MXHpcohq[mm2czDj[YxtKGe{b4f0bC=> MYGyN|E3QTF2OB?=
Hep3B  NFvJWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fxV|HjiJN3wsXN NVXmempwOjRxNEivO|IhcA>? M4HmSIlvcGmkaYTzJINmdGxiZ4Lve5Rp Mm\VNlMyPjlzNEi=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
in solvent
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03081494 Recruiting Metastatic Colorectal Cancer Novartis Pharmaceuticals|Novartis June 9 2017 Phase 1
NCT02042144 Completed Neoplasms Bayer April 8 2014 --
NCT01298570 Active not recruiting Colorectal Cancer Metastatic UNC Lineberger Comprehensive Cancer Center|Bayer April 7 2011 Phase 2
NCT03099486 Recruiting Colorectal Cancer Fox Chase Cancer Center October 6 2017 Phase 2
NCT02080260 Completed Pancreatic Cancer Stuart Salmon MD|Bayer|Carolinas Healthcare System June 6 2014 Phase 2
NCT02788279 Active not recruiting Colorectal Cancer Hoffmann-La Roche July 5 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to resuspend Regorafenib for in vivo studies?

  • Answer:

    For in vivo study, we recommend to use 2% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 5mg/ml.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID